U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07671833) titled 'A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects' on April 14.
Brief Summary: This is an open-label, single-dose, parallel-group study to evaluate the safety, tolerability and pharmacokinetic characteristics of LY03015 in healthy Chinese and Caucasian adult subjects. The duration of study will be around up to 42 days for each participant, including up to 14 days of screening period, baseline visit, and a 28-day safety assessment period with a 7-day/6-night stay in the clinical research unit.
Study Start Date: April 15
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: LY03015 (LPM3...